Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.30 (3.59%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £56.68m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Sole source supplier contract from DARPA

22 Feb 2016 07:00

RNS Number : 6741P
Kromek Group PLC
22 February 2016
 

 

Approved for Public Release, Distribution Unlimited

22 February 2016

Kromek Group plc

("Kromek" or the "Company")

 

Kromek Signs Second contract with DARPA

US defence agency appoints Kromek as sole source supplier under SIGMA programme to deliver D3S detectors in mass volume

 

Further to the announcement of 8 October 2015, Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, announces that the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, has confirmed the award of a sole source contract to Kromek to supply spectroscopic personal radiation detectors (D3S) in support of DARPA's SIGMA programme. The contract also includes an additional award for an accessory for the D3S. The total value of the contract is $6.0m with delivery commencing immediately.

 

Under the terms of the contract, Kromek will deliver the D3S detectors during the current and next financial year and will also supply up to 12,000 Inductive Charging packs for D3S detectors and associated mobile devices over the same period. The Inductive Charging pack has an innovative deployable capability for high volume daily usage of the detectors and the methodology for both charging and recalibrating where necessary.

 

Arnab Basu, Chief Executive Officer of Kromek, said: "The D3S is the world's first fully approved combined gamma and neutron detector available in volume shipment and at a market leading unit price of $400, which is also available to other user organisations buying over 10,000 detectors in a single procurement. It is a significant breakthrough for us and we are pleased to have achieved the technological advancement that has enabled DARPA to be ahead of their own original programme performance expectations. We look forward to successfully delivering on the contract."

 

 

Enquiries:

 

Kromek Group plc

01740 626 060

Arnab Basu, CEO

Derek Bulmer, CFO

 

 

 

Cenkos Securities plc

0207 397 8900

Bobbie Hilliam (NOMAD)

Julian Morse, Michael Johnson (Sales)

 

 

 

Luther Pendragon Ltd

0207 618 9100

Harry Chathli, Claire Norbury, Alexis Gore

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTGGGDDCGDBGLD
Date   Source Headline
4th Apr 20227:00 amRNSNew £1.7m CBRN contract
18th Jan 20227:00 amRNSInterim Results
17th Dec 20214:41 pmRNSSecond Price Monitoring Extn
17th Dec 20214:35 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSNotice of Results
26th Oct 20217:00 amRNSKromek awarded contract by US based OEM customer
29th Sep 20213:14 pmRNSHolding(s) in Company
27th Sep 20211:47 pmRNSDirector Share Purchase
23rd Sep 20217:00 amRNSNuclear security contract from US federal entity
8th Sep 202111:09 amRNSResult of AGM
13th Aug 20213:48 pmRNSNotice of AGM and Publication of Annual Report
3rd Aug 202112:25 pmRNSHolding(s) in Company
15th Jul 202111:05 amRNSSecond Price Monitoring Extn
15th Jul 202111:00 amRNSPrice Monitoring Extension
14th Jul 20217:00 amRNSFinal Results
14th Jul 20217:00 amRNSNew Contracts
1st Jul 20217:00 amRNSNotice of Results
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSKromek awarded new DARPA bio-threat contract
12th May 20212:50 pmRNSDirector Share Purchase
11th May 20217:00 amRNSBusiness and Trading Update
21st Apr 20214:32 pmRNSHolding(s) in Company
9th Mar 20217:00 amRNSKromek awarded Nuclear Detection contract
4th Mar 20211:32 pmRNSHolding(s) in Company
2nd Mar 20218:30 amRNSPDMR Dealings
1st Mar 20212:53 pmRNSResults of Placing, Open Offer and General Meeting
1st Mar 20217:00 amRNSNew Medical Screening and Nuclear Security orders
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
15th Feb 20217:00 amRNSPosting of Circular
12th Feb 202111:05 amRNSSecond Price Monitoring Extn
12th Feb 202111:00 amRNSPrice Monitoring Extension
12th Feb 202110:30 amRNSPlacing and Open Offer to raise up to £13 million
4th Feb 20212:00 pmRNSIssue of Equity and Total Voting Rights
26th Jan 20215:15 pmRNSHolding(s) in Company
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:35 pmRNSPrice Monitoring Extension
22nd Jan 20212:05 pmRNSSecond Price Monitoring Extn
22nd Jan 20212:00 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20219:35 amRNSHolding(s) in Company
13th Jan 20217:01 amRNSFunding to advance Bio-Threat Detection solution
13th Jan 20217:00 amRNSInterim Results
7th Jan 202111:05 amRNSSecond Price Monitoring Extn
7th Jan 202111:01 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSDirectorate Changes
14th Dec 202012:45 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.